Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 6/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23651895 | 0.80 | NCF1 (0.46) | — | |
| SCHEMBL3317239 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL485135 | 0.79 | ALOX5 (0.45) | ALOX5EPHX2AKR1C3HTR2CITGB3 | |
| SCHEMBL4578235 | 0.77 | ALOX5 (0.44) | ALOX5EPHX2AKR1C3HTR2CITGB3 | |
| SCHEMBL3314951 | 0.77 | CYP1A2 (0.44) | ALOX5EPHX2AKR1C3 | |
| SCHEMBL7963367 | 0.77 | ALOX5 (0.44) | ALOX5EPHX2AKR1C3HTR2CITGB3 | |
| SCHEMBL1713095 | 0.77 | ALOX5 (0.44) | ALOX5EPHX2AKR1C3ITGB3ITGA2B | |
| SCHEMBL1713090 | 0.76 | ALOX5 (0.42) | ALOX5EPHX2AKR1C3HTR2CITGB3 | |
| SCHEMBL7365311 | 0.76 | CHRNB2 (0.57) | ALOX5POLB | |
| SCHEMBL20300505 | 0.76 | ALDH1A1 (0.50) | ALOX5EPHX2AKR1C3POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | DONG-A-PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| EP-2137152-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114971-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | HTR4, HTR1A, TPH1 | ALOX5 1005/4885EPHX2 3996/4885AKR1C3 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.